Spruce Street Capital LP is an SEC-registered investment adviser based in New York, NY that reports managing 3 hedge funds on Form ADV. It reports $555.9 million in regulatory assets under management. Its private funds, of all types, hold $900.9 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +62.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +62.5% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $555.9 millionForm ADV Item 5.F
- Gross assets of private funds
- $900.9 millionAll private fund types, Form ADV
- Hedge funds managed
- 33 private funds in total
- Employees
- 4Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 333213
- Latest Form ADV
- 03/02/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +20.3% | +14.8% |
| Q1 2026 | +35.1% | -4.6% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 39 share positions ($628,983,538) reported by Spruce Street Capital LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Kiniksa Pharmaceuticals Intl10.89%
- LB Pharmaceuticals Inc8.56%
- Relay Therapeutics Inc8.56%
- Alto Neuroscience Inc6.80%
- Alkermes PLC6.11%
- Entera Bio LTD5.19%
- Dianthus Therapeutics Inc4.97%
- Savara Inc4.42%
- Zai Lab LTD4.36%
- Relmada Therapeutics Inc4.14%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Kiniksa Pharmaceuticals Intl | $68,497,203 | 10.89% | 918,070 | Unchanged |
| LB Pharmaceuticals Inc | $53,863,456 | 8.56% | 1,404,779 | +2.08% |
| Relay Therapeutics Inc | $53,863,456 | 8.56% | 2,984,125 | Unchanged |
| Alto Neuroscience Inc | $42,802,526 | 6.80% | 1,676,558 | +23.91% |
| Alkermes PLC | $38,432,045 | 6.11% | 948,471 | +74.39% |
| Entera Bio LTD | $32,631,154 | 5.19% | 11,213,455 | New |
| Dianthus Therapeutics Inc | $31,241,549 | 4.97% | 354,816 | Unchanged |
| Savara Inc | $27,770,816 | 4.42% | 5,381,941 | +55.88% |
| Zai Lab LTD | $27,450,442 | 4.36% | 1,042,158 | +273.39% |
| Relmada Therapeutics Inc | $26,058,960 | 4.14% | 6,912,191 | +8.15% |
| Vaxcyte Inc | $17,414,074 | 2.77% | 306,047 | Unchanged |
| Obsidian Therapeutics Inc | $17,161,717 | 2.73% | 1,249,943 | New |
| Enliven Therapeutics Inc | $15,081,635 | 2.40% | 329,006 | Unchanged |
| Enanta Pharmaceuticals Inc | $14,349,475 | 2.28% | 1,088,731 | Unchanged |
| Surrozen Inc | $13,903,047 | 2.21% | 432,040 | Unchanged |
| Sagimet Biosciences Inc | $13,832,000 | 2.20% | 1,400,000 | New |
| Yarrow Bioscience Inc | $13,678,243 | 2.17% | 607,382 | New |
| Inflarx NV | $10,955,106 | 1.74% | 6,086,170 | +13.71% |
| Korsana Biosciences Inc | $10,304,110 | 1.64% | 338,951 | New |
| Perspective Therapeutics Inc | $10,158,310 | 1.62% | 3,693,931 | Unchanged |
| An2 Therapeutics Inc | $9,320,699 | 1.48% | 1,752,011 | +5.47% |
| Inhibikase Therapeutics Inc | $7,360,194 | 1.17% | 3,581,603 | Unchanged |
| Sab Biotherapeutics Inc | $6,969,251 | 1.11% | 2,198,502 | Unchanged |
| Century Therapeutics Inc | $6,940,982 | 1.10% | 4,059,054 | Unchanged |
| Erasca Inc | $6,194,480 | 0.98% | 422,543 | Unchanged |
| Achieve Life Science Inc | $5,959,393 | 0.95% | 736,637 | Unchanged |
| Minerva Neurosciences Inc | $5,545,925 | 0.88% | 1,655,500 | Unchanged |
| Research Alliance Corp III | $5,415,000 | 0.86% | 500,000 | Unchanged |
| Research Alliance Corp IV | $5,400,000 | 0.86% | 450,000 | New |
| Helix Acquisition Corp III | $5,310,000 | 0.84% | 500,000 | Unchanged |
| Attovia Therapeutics Inc | $3,912,976 | 0.62% | 228,295 | New |
| Alector Inc | $3,886,976 | 0.62% | 2,101,068 | Unchanged |
| Tcgx Acquisition Corp | $3,753,000 | 0.60% | 300,000 | New |
| Lexeo Therapeutics Inc | $3,138,644 | 0.50% | 928,593 | Unchanged |
| Alumis Inc | $2,901,122 | 0.46% | 392,574 | Unchanged |
| Corvus Pharmaceuticals Inc | $2,667,859 | 0.42% | 231,585 | Unchanged |
| Jatt II Acquisition Corp | $1,799,200 | 0.29% | 160,000 | Unchanged |
| Jatt III Acquisition Corp | $1,653,000 | 0.26% | 150,000 | New |
| Leonabio Inc | $1,405,513 | 0.22% | 393,701 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 9 new positions, 0 sold out, 8 increased, 0 reduced and 22 unchanged.
Number of positions (a count, not dollars)
- New positions9
- Increased8
- Unchanged22
- Reduced0
- Sold out0
New positions
| Stock | Value | Shares |
|---|---|---|
| Entera Bio LTD | $32,631,154 | 11,213,455 |
| Obsidian Therapeutics Inc | $17,161,717 | 1,249,943 |
| Sagimet Biosciences Inc | $13,832,000 | 1,400,000 |
| Yarrow Bioscience Inc | $13,678,243 | 607,382 |
| Korsana Biosciences Inc | $10,304,110 | 338,951 |
| Research Alliance Corp IV | $5,400,000 | 450,000 |
| Attovia Therapeutics Inc | $3,912,976 | 228,295 |
| Tcgx Acquisition Corp | $3,753,000 | 300,000 |
| Jatt III Acquisition Corp | $1,653,000 | 150,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Zai Lab LTD | +763,048 | +273.39% | $27,450,442 | 1,042,158 |
| Alkermes PLC | +404,595 | +74.39% | $38,432,045 | 948,471 |
| Savara Inc | +1,929,365 | +55.88% | $27,770,816 | 5,381,941 |
| Alto Neuroscience Inc | +323,511 | +23.91% | $42,802,526 | 1,676,558 |
| Relmada Therapeutics Inc | +520,863 | +8.15% | $26,058,960 | 6,912,191 |
| Inflarx NV | +733,972 | +13.71% | $10,955,106 | 6,086,170 |
| LB Pharmaceuticals Inc | +28,620 | +2.08% | $53,863,456 | 1,404,779 |
| An2 Therapeutics Inc | +90,938 | +5.47% | $9,320,699 | 1,752,011 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Yarrow Bioscience, Inc. | 13G | 6.4% | 607,382 | Nov 13, 2026 | SEC.gov ↗ |
| Research Alliance Corp IV | 13G | 5.8% | 450,000 | Nov 13, 2026 | SEC.gov ↗ |
| Entera Bio Ltd. | 13G | 6.4% | 11,213,455 | Nov 13, 2026 | SEC.gov ↗ |
| LeonaBio, Inc. | 13G | 4.2% | 393,700 | Nov 13, 2026 | SEC.gov ↗ |
| Research Alliance Corp III | 13G | 6.4% | 500,000 | Aug 13, 2026 | SEC.gov ↗ |
| Relmada Therapeutics, Inc. | 13G | 5.57% | 4,086,181 | Feb 17, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Feb 17, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures